Tests methylprednisolone with clot removal for large acute ischemic stroke
Tests methylprednisolone alongside clot removal in adults with large acute strokes.
Plain-language title generated from the registry record
Registry title: Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke caused by a blocked large brain artery, who have a large area of damaged brain and will have a clot-removal procedure (thrombectomy).
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Sudden (acute) ischemic stroke with NIHSS 6 or higher, within 24 hours of last known well. A blocked artery (internal carotid, M1 or M2) confirmed on imaging. A large damaged area: ASPECTS 0-5, or core volume 70 mL or more. Before the stroke, mRS score of 0-1.
- Earlier treatment
- A clot-removal procedure (EVT) must be planned. Taking part in another interventional trial now is not allowed.
Main reasons for not taking part
- Bleeding in the brain on CT or MRI
- Allergy to corticosteroids or contrast agents
- Blood sugar above 22.2 mmol/L (400 mg/dL)
- Bleeding disorder or certain blood thinners; platelets below 90×10⁹/L
- Pregnant or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07175649, who can take part
Where in China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Xinguang Yang, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Trial code
- NCT07175649
- Record updated
- 16 September 2025
- Original description
It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vessel occlusion (LVO) patients with a large infarct core. In this study, the investigators hypothesize that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone in patients with evidence of a large infarct volume. The primary objective of the study is to establish the efficacy of methylprednisolone with EVT in patients with acute anterior circulation LVO and a large infarct core.Read full original descriptionShow less
Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke: A Randomized, Double-blind, Placebo-controlled Trial
It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vessel occlusion (LVO) patients with a large infarct core. In this study, the investigators hypothesize that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone in patients with evidence of a large infarct volume. The primary objective of the study is to establish the efficacy of methylprednisolone with EVT in patients with acute anterior circulation LVO and a large infarct core.
Inclusion: Aged 18 to 85 years; Clinically diagnosed acute ischemic stroke with screening NIHSS ≥6; Time from last known well to randomization ≤24 hours; Pre-stroke mRS score of 0-1; Occlusion of the responsible vessel confirmed by CT angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA) in intracranial segment of internal carotid artery (ICA), M1 or M2 segment of middle cerebral artery (MCA), and plan to undergo EVT; Alberta Stroke Program Early CT Score (ASPECTS) of 0-5 on NCCT, or ischemic core volume ≥70 mL (defined as regional cerebral blood flow [rCBF] <30% on CT perfusion [CTP] or apparent diffusion coefficient [ADC] <620×10-⁶ mm²/s on MRI); Informed consent obtained.
Exclusion: Severe infectious disease unsuitable for corticosteroid therapy or concurrent contraindications to corticosteroid treatment; Intracranial hemorrhage on NCCT or MRI; Allergy to corticosteroids; Allergy to contrast agents; History of gastrointestinal or urinary tract bleeding within the last month; Life expectancy <6 months due to terminal illnesses such as malignancy or severe cardiopulmonary disease; Other conditions deemed unsuitable for study participation by the investigator, including inability to comprehend and/or comply with study procedures and/or follow-up due to psychiatric, cognitive, or emotional disorders; Random blood glucose >22.2 mmol/L (400 mg/dL); Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, use of warfarin with an international normalized ratio (INR) >1.7, or administration of novel oral anticoagulants within 48 hours of symptom onset; Platelet count <90×10⁹/L; Renal dysfunction with an estimated glomerular filtration rate (eGFR) <30 mL/min or serum creatinine >220 μmol/L (2.5 mg/dL); Current participation in another interventional clinical trial; Pregnancy or lactating; Persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg despite antihypertensive treatment; Intracranial aneurysm or arteriovenous malformation; Intracranial tumour with mass effect on imaging (except for small meningiomas).